Introduction {#S1}
============

Interferon Regulatory Factor 6 (IRF6) drives the differentiation of epithelia with barrier function via unknown mechanisms. In mice deficient for *Irf6*, epidermal keratinocytes fail to differentiate terminally, resulting in the absence of an epidermal permeability barrier ([@R14]; [@R34]; [@R4]). Moreover, the superficial layer of the oral epithelium, the oral periderm is missing, resulting in adhesion between the palatal shelves and the tongue ([@R33]). Mutations in *IRF6* cause two syndromic forms of cleft lip and palate (CL/P): Van der Woude and Popliteal Pterygium syndromes ([@R19]). They are also associated with non-syndromic CL/P ([@R44]; [@R17]; [@R38]; [@R30]; [@R8]). In patients with such mutations, abnormal differentiation of the epidermis or oral periderm may contribute to CL/P pathogenesis of CL/P. In addition, IRF6 appears to be necessary for normal wound healing ([@R16]), promotes differentiation of the breast epithelium ([@R2]), and functions as a tumor suppressor in squamous cell carcinoma ([@R6]). A recent study identified hundreds of genomic loci that are bound by IRF6 in human keratinocytes ([@R6]), but it is unclear which of these apparent transcriptional targets effect epithelial differentiation.

The aim of this study was to characterize the position of Irf6 within the gene regulatory network that controls differentiation of the periderm in zebrafish, as many aspects of mammalian skin biology are conserved in fish ([@R21]). The periderm is a simple squamous epithelium that is the most superficial layer of an embryo and forms the first permeability barrier to dehydration in mouse embryos ([@R23]). In both fish and amphibian embryos, the periderm forms in early gastrula stage and is necessary for structural integrity of the embryo during this period ([@R11]). We previously showed that the periderm was disrupted in both zebrafish embryos injected with RNA encoding a dominant-negative Irf6 variant (dnIrf6) and in frog embryos depleted of maternal Irf6: the expression of various periderm markers was lost, and the periderm itself ruptured ([@R36]). Here, through microarray analysis, *in vivo* reporter studies, and epistasis experiments, we identify the gene encoding Grainyhead-like 3 (*Grhl3*), an ancient mediator of epithelial integrity, as a direct effector of Irf6 in periderm differentiation.

Results {#S2}
=======

Potential regulators of periderm differentiation {#S3}
------------------------------------------------

We assessed the gene expression profile of isolated zebrafish periderm cells using the *Tg(krt4:gfp*) transgenic zebrafish line, in which GFP is robustly expressed in simple epithelia of the embryo ([@R13]). Through cell sorting and microarray analyses, we identified a subset of genes expressed in GFP^+^ cells at levels at least three-fold higher than in GFP^−^ cells ([Fig.1a,b](#F1){ref-type="fig"}). This "periderm-enriched profile" ([Supplemental Table S1](#SD2){ref-type="supplementary-material"}) is significantly enriched for genes with ontology terms typical of those present in other epithelia (See Methods). The seventy transcription factor-encoding genes represented in this profile ([Table S1](#SD2){ref-type="supplementary-material"}) potentially participate in the periderm gene regulatory network, either upstream or downstream of Irf6.

To learn where Irf6 fits into this network, we created a profile of genes whose expression is altered in the presence of dnIrf6. We did not use antisense morpholino oligonucleotides (MO), the standard tools for reducing gene expression in zebrafish embryos, because they are commonly ineffective against maternally-encoded transcripts ([@R9]) and this proved to be the case for *Irf6* ([Fig. S1](#SD1){ref-type="supplementary-material"}). Instead we modified the dnIrf6 generated for our earlier study([@R36]) by fusing the Irf6 DNA-binding domain to the Engrailed repressor domain. We injected embryos with an RNA encoding either dnIrf6 or β-galactosidase (i.e. *lacZ* RNA), harvested RNA at 6 hours post fertilization (hpf; such embryos rupture by 7 hpf), and probed microarrays as described above. We identified a subset of genes that are expressed at significantly lower levels in *dnIrf6*-injected than in *lacZ*-injected embryos, and refer to this as the "dnIrf6-inhibited profile" ([Fig.1c,d](#F1){ref-type="fig"}, [Table S2](#SD2){ref-type="supplementary-material"}); it contains many genes that encode adhesion molecules, consistent with rupture of the periderm in dnIrf6-injected embryos.

Of the genes present in both the periderm-enriched and dnIrf6-inhibited profiles ([Fig. 1E](#F1){ref-type="fig"}) ([Table S3](#SD2){ref-type="supplementary-material"}), ten are classified by the gene ontology term, "transcription factor activity," and therefore may participate in the periderm gene regulatory network that acts downstream of Irf6 ([Table 1](#T1){ref-type="table"}). Among these, *grhl1* and *klf2b* are of special interest because homologues of these genes, *Grhl3* and *Klf4*, respectively, are required to generate the epidermal permeability barrier in mice ([@R41]) ([@R37]). However, probes for the zebrafish orthologs of neither *Grhl3* nor *Klf4* are present in the microarray we deployed. Therefore we assessed the expression of these genes, and that of several others common to the two profiles, by *in situ* hybridization. We found that all are indeed down-regulated in *dnIrf6*-injected embryos vs. control-injected embryos ([Fig. 1f-w](#F1){ref-type="fig"}), and that *epcam*, which is present in only the former profile, is indeed expressed in dnIrf6-injected embryos ([Fig. 1x,y](#F1){ref-type="fig"}). Moreover, we found that co-injecting an RNA encoding full-length Irf6 partially reversed the effects of *dnIrf6* ([Fig. 1z](#F1){ref-type="fig"}), supporting the idea that those effects result from interference with Irf6 and/or closely related proteins. Genes in the periderm-enriched profile whose expression was significantly *elevated* in the presence of dnIrf6 are candidates for repression by Irf6, although most are likely affected indirectly because dnIrf6 is a constitutive repressor. Interestingly, *p63*, which regulates epidermal differentiation in mice and zebrafish, and directly regulates Irf6 expression, ranks among these genes ([@R3]; [@R20]; [@R28]; [@R40]). In summary, profling experiments revealed several genes that are likely to be members of the periderm gene regulatory network that act downstream of Irf6.

Irf6 activates epithelial enhancers adjacent to *Grhl3* {#S4}
-------------------------------------------------------

We next sought to test the possibility that Irf6 directly activates *grhl3* expression in the periderm. In a recent ChIP experiment conducted in human keratinocytes, IRF6 was found to be bound at two locations near the first exon of *GRHL3* -- about 2 kb upstream, and about 3 kb downstream (intronic) ([Fig. 2a](#F2){ref-type="fig"}) ([@R6]). Both peaks are within chromatin elements that are conserved among mammals and are sites of DNAse hypersensitivity in human keratinocytes (ENCODE project). Thus, these elements may have cis-regulatory function. In addition, microarray analysis revealed that *GRHL3* expression is reduced in cells depleted of *IRF6*, suggesting that IRF6 directly activates *GRHL3* expression in keratinocytes ([@R6]). To test this possibility, we amplified the conserved elements containing these peaks and cloned them into a firefly luciferase reporter vector containing a minimal promoter ([Fig. 2a](#F2){ref-type="fig"}). In a human keratinocyte cell line transfected with the construct containing the intron-1 element, but not in one tranfsected with the construct containing the the upstream element, luciferase levels were significantly higher than in a line transfected with a control-construct ([Fig. 2b](#F2){ref-type="fig"}). Although neither IRF6-bound element is detectably conserved in zebrafish, the functions of mammalian enhancer elements without detectable counterparts in zebrafish often nonetheless are conserved in zebrafish embryos ([@R10]; [@R26]; [@R25]). We thus cloned the elements into a reporter vector that contains a minimal promoter and the gene encoding green fluorescent protein (GFP)([Fig. 2a](#F2){ref-type="fig"}) (vector described in [@R10]), and injected these constructs into wild-type zebrafish embryos. About 20% of the embryos injected with *hGRHL3_peak2:gfp* exhibited GFP expression in contiguous patches of periderm cells (recognizable due to their characteristic polygonal morphology), starting at high stage and continuing to at least 72 hpf (shown on the yolk at 48 hpf, [Fig. 2c](#F2){ref-type="fig"}) (numbers of injected embryos for reporter experiments are presented in Methods). Embryos injected with *hGRHL3_peak1:gfp* or the vector lacking either element did not exhibit these patches. These studies support the idea that Irf6 directly activates Grhl3 expression in both human keratinocytes and the zebrafish periderm.

As an alternative approach for identifying Irf6-dependent enhancers, we searched mammalian and zebrafish genomes for the presence of conserved, non-coding elements that possess the consensus Irf6 response element ([@R22]). Although we did not detect any that are conserved between mammals and zebrafish, we found one (within intron 15 of *GRHL3*) that is conserved among mammals ([Fig. 2d](#F2){ref-type="fig"}). Although IRF6 binding of this site was not reported in keratinocytes ([@R6]), it could potentially occur in other cell types including those of the periderm. Indeed, we found that an oligonucleotide that matches *Grhl3* intron sequence encompassing the apparent Irf6 binding site competes with a control probe for the binding of Irf6DBD *in vitro*, and that a version of the oligo in which this site has been altered lacks this ability ([Fig. 2e](#F2){ref-type="fig"}). To test the potential enhancer activity of the conserved element within *GRHL3* intron 15, we amplified it (972 bp) from the murine genome and cloned it into the GFP reporter vector (creating *mGrhl3intron15:gfp)*. In both transient and stable transgenic embryos harboring this construct, GFP is expressed in the periderm ([Fig 2f,h](#F2){ref-type="fig"}). In addition, we generated a construct in which six bases within the Irf6RE are mutated (as in the *in vitro* binding experiment described above), creating *intron15ΔIrf6RE:gfp* ([Fig. 2g](#F2){ref-type="fig"}). In embryos injected with this construct, GFP expression was rarely detected in periderm cells, and was completely extinguished by 48 hpf ([Fig. 2g](#F2){ref-type="fig"}). In summary a conserved element within intron 15 of mammalian *Grhl3* has periderm enhancer activity that depends on the presence of a consensus Irf6 binding site.

Inhibition of *grhl1* and *grhl3* disrupts periderm development {#S5}
---------------------------------------------------------------

Three members of the Grhl family are expressed in the zebrafish periderm ([@R15]). Because Grhl family members share a core DNA consensus binding site ([@R41]; [@R42]; [@R35]) ([@R5]), we reasoned that overexpressing the DNA binding domain (DBD) of any is likely to displace them all from DNA. We thus injected zebrafish embryos with an RNA encoding the *Xenopus* Xgrhl1 DBD *(dnXgrhl1)*. This resulted in stalled epiboly and embryonic rupture, much as in *dnIrf6*-injected embryos (not shown, 29 of 30 injected embryos)([@R39]). We found that mosaic injection of the *dnXgrhl1* blocked *krt4* expression in cell-autonomous fashion ([Fig. 3a,b](#F3){ref-type="fig"}). To determine which family members are essential for development of the zebrafish periderm, we injected MOs known to target the *grhl1* start codon ([@R15]) or to block the splicing of *grhl3* (confirmed in [Fig. S2](#SD1){ref-type="supplementary-material"}). Epiboly was not affected when either was injected alone, but when both were injected simultaneously, the expression of *krt4*, *capn9*, and *ovol1b* was significantly reduced, epiboly was delayed, and the embryos ruptured at the animal pole ([Fig. 3c--j](#F3){ref-type="fig"}). RT-PCR confirmed that the combination of MOs targeting *grhl1* and *grhl3* reduced expression of *krt4* ([Fig. S2](#SD1){ref-type="supplementary-material"}). Thus, Grhl1 and Grhl3 function redundantly to promote periderm differentiation in zebrafish.

Forced expression of *grhl3* partially restores epiboly in dnIrf6-injected embryos {#S6}
----------------------------------------------------------------------------------

During epiboly, blastomeres in control embryos migrate towards the vegetal pole, producing doming of the yolk towards the animal pole ([Fig. 4b,h](#F4){ref-type="fig"}). In the large majority of embyros injected with *dnIrf6* mRNA and subsequently injected with a control mRNA (i.e., *lacZ*), these movements do not appear to occur ([Fig. 4g and 4h](#F4){ref-type="fig"}), and virtually all have ruptured through the animal pole by the time control embryos reach 6.5 hpf ([Fig. 4b](#F4){ref-type="fig"}) (94%, n=114 injected embryos). By contrast, in the majority of *dnIrf6* -injected embryos that are instead injected with the *grhl3* mRNA, blastomeres move towards the vegetal pole, the yolk undergoes doming, and embryos are still alive at 6.5 hpf ([Fig. 4c,f,i](#F4){ref-type="fig"}) (70%, n=119). Moreover they express the periderm markers *claudinE*, *capn9*, and *ovol1* at higher levels, as demonstrated by qRT-PCR analysis ([Fig. 4j](#F4){ref-type="fig"}) and confirmed by *in situ* hybridization for *capn9* ([Fig. 4k--m](#F4){ref-type="fig"}). Most such embryos nonetheless ultimately rupture by the time control embryos reach 7.5 hpf (81%, n=119). Thus *grhl3* mRNA improved survival during epiboly of dnIrf6-injected embryos without obviously rescuing the overall morphology of embryos.

We also tested the ability of Grhl3 to reverse the effects of MO-mediated knockdown of the *irf6* mRNA in frog embryos. Using the oocyte-transfer method to inhibit maternal *irf6*, we confirmed the earlier report ([@R36]) of a strong reduction of the superficial epithelium marker *Xk81a1* and up-regulation of the deep-cell marker, *sox11* ([Fig. 4n](#F4){ref-type="fig"}). In embryos that were additionally injected with the *Xenopus grhl3* mRNA, *xk81a1* levels were significantly closer to those in control embryos ([Fig. 4n](#F4){ref-type="fig"}). Thus, Irf6-mediated activation of *grhl3* expression appears to be a critical component in the periderm gene regulatory network in fish and in frogs.

Expression of *Grhl3* in murine *Irf6*-deficient embryos {#S7}
--------------------------------------------------------

We harvested epidermis from mouse embryos that expressed wild-type and/or a null allele of *Irf6* (i.e., homozygous control, heterozgous mutant or homozygous mutant) at E14.5 and E17.5, and measured *Grhl3* levels by qRT-PCR. In homozygous mutants, *Grhl3* was reduced at E14.5 but elevated at E17.5 with respect to the levels in siblings (wild-type or heterozygous mutant) ([Fig. 5a](#F5){ref-type="fig"}). The elevation at the later time point is consistent with the observation that epidermal stratification is abnormal (the basal and spinous layers are expanded and exhibit inappropriate gene expression, and the granulosum and cornified layers are absent) ([@R14]; [@R34]). To determine the reason for the reduction of *Grhl3* expression at E14.5, we evaluated anti-Grhl3 immunoreactivity (Grhl3 IR) in coronal head sections from homozgyous *Irf6* mutants and their siblings at E14.5. In the sibling embryos, nuclear Grhl3 IR was detected in all layers of the epidermis, with expression highest in periderm-cell nuclei ([Fig. 5b](#F5){ref-type="fig"}). In *Irf6* mutants, Grhl3 IR was generally lower and non-nuclear, and the characteristic periderm expression was absent ([Fig. 5c](#F5){ref-type="fig"}). Similar changes in the gene expression pattern and the epidermal structure were observed in the oral epithelium ([Fig. 5d,e](#F5){ref-type="fig"}). Together these findings suggest that Irf6 directly activates *Grhl3* expression in the periderm and oral epithelium in mice, but that in keratinocytes, Irf6 contributes to the activation of *Grhl3* expression, but is not essential for it.

Finally, we generated mutants doubly heterozygous for Irf6 and Grhl3. In newborn *Irf6^gt/+^; Grhl3^del/+^* pups, we detected neither gross morphological defects in the face, ears, limbs or oral cavity, nor obvious histological defects in skin or oral epithelium (n=6) (not shown). Thus, if Irf6 and Grhl3 function in the same pathway during formation of the permeability barrier, the dosage of neither gene is limiting in double heterozygotes.

Discussion {#S8}
==========

Irf6 and the periderm gene regulatory network {#S9}
---------------------------------------------

Here we have conducted profiling experiments that have shed light on the role of Irf6 in zebrafish periderm development. We used conservative criteria in identifying genes in the in the periderm-enriched and dnIrf6-inhibited profiles, and probes for some of the genes that are important for epithelial development, including *grhl3* itself, were not represented on the microarray we deployed. Nonetheless, the periderm-enriched profile includes at least seventy genes encoding transcription factors, all of which are candidate participants in the periderm transcriptional gene regulatory network. Those that are also present in the *dnIrf6*-inhibited profile include *grhl1*, *tfap2c*, *klf2b,* and *c/ebp beta*. Each of these genes or a homologue has previously been implicated in epithelial development. Notably, many of the regulatory genes in the periderm profile are not in the *dnIrf6*-sensitive profile, and these could play roles upstream of, or parallel to, Irf6 during epithelial development. Candidates for regulatory proteins acting upstream of Irf6 include aPKC ([@R7]), Ikk1 ([@R11]), and p63 ([@R28]; [@R40]). Thus, our work has helped to place Irf6 within the gene regulatory network that governs differentiation of the zebrafish periderm, a tissue that serves as a model for other simple squamous epithelia, including mammalian oral periderm.

Grhl3 appears to be a direct effector of Irf6 in the periderm {#S10}
-------------------------------------------------------------

Our results suggest that Irf6 directly regulates *grhl3* expression, and that in some tissues it may do so in conjunction with other Irf family members. Specifically, we show that *Grhl3* expression is strongly down regulated in the periderm of zebrafish embryos injected with dnIrf6, consistent with previous findings from *Xenopus* embryos derived from oocytes injected with *irf6* MO ([@R36]), *Irf6* mutant mouse embryos ([@R14]; [@R34]), and human keratinocytes transfected with an shRNA targeting human IRF6 ([@R6]). Moreover, we have identified two conserved non-coding elements close to *GRHL3* -- one known to be bound by IRF6 in keratinocytes, and another strongly conserved Irf6 consensus binding site -- that both have zebrafish periderm enhancer activity. We have also found that *Grhl3* expression is not completely dependent on Irf6 in all tissues, for instance in mouse keratinoctyes; it is possible that in such contexts Irf6 homologues cooperate with Irf6 to regulate target-gene expression. We note that the periderm-enriched profile includes two *irf6* homologues (i.e., *irf4a* and *irf11*). The presence of these genes, together with maternally encoded *irf6*, may explain why dnIrf6 effectively reduces *grhl3* expression upon injection into zebrafish eggs, whereas the irf6 MO does not (our unpublished finding). We note also, that a ChIP-SEQ experiment found that IRF4 binds intron 15 of *GRHL3* in a lymphoblast cell line (ENCODE project, Rick Myers laboratory, HudsonAlpha Institute). In summary, the available genetic and biochemical evidence indicates that Irf6, possibly in conjunction with its homologs, directly activates *grhl3* expression in epithelial structures.

Clinical and evolutionary implications {#S11}
--------------------------------------

Because Grhl3 appears to act in concert with Irf6 in the oral periderm gene regulatory network, mutations in *GRHL3*, and in genes encoding other members of this network, are candidates to contribute risk for CL/P. Whereas mutations in *IRF6* have been estimated to confer 12% of inherited risk for non-syndromic CL/P ([@R44]), the majority of such risk has not been ascribed to any gene ([@R43]). In mice, Irf6 is necessary for differentiation of the oral epithelium, particularly that of the oral periderm ([@R33]). *Grhl3* is expressed in the zebrafish oral epithelium (our unpublished findings) and in mouse embryos ([@R1]). Furthermore, as recently reported, mouse *Grhl2* mutants exhibit orofacial clefts ([@R32]). Although our macroscopic analyses of *Irf6^gt/+^;Grhl3^del/+^* double heterozygous mice at birth did not detect gross anomalies in skin development, it will be important to assess embryos for the presence of oral adhesions. Importantly, the absence of a phenotype in double heterozygotes is not strong evidence against two genes acting in the same pathway. Indeed, the related defects in barrier function in *Grhl3* and *Irf6* mutants suggests that the two genes promote skin differentiation through the same pathway ([@R41]; [@R14]; [@R34]). Also, the ability of *Grhl3* to rescue the expression of periderm markers in dnIrf6-injected embryos, as shown here, is strong evidence that they act in the pathway that promotes periderm differentiation. The data presented here motivate an assessment of over-transmission of specific alleles of *GRHL3* (or other *GRHL* family members) in patients with non-syndromic CL/P, and of mutations in *GRHL3* in patients with syndromic forms of CL/P. In this context it is intriguing that three linkage studies have detected a risk locus at 1p36, where GRHL3 resides ([@R31]; [@R24]; [@R27]), and Van der Woude Syndrome 2 (VWS2), which includes oro-facial clefting, maps to an interval that contains *GRHL3* ([@R18]).

Finally, our data lead us to speculate how the role of IRF6 in epithelial development evolved. The IRFs are ancient, having arisen alongside muticellurity in animals ([@R29]), and the GRHL family has an ancient role in promoting barrier formation ([@R41]). Most members of the IRF family regulate the expression of genes that encode interferons and proteins that promote the differentiation of dendritic cells ([@R12]); a unifying theme of targets of other IRFs is an involvement in innate immunity. However, given that the most important aspect of innate immunity is the epidermal permeability barrier, it is plausible that GRHL3 activation is not a novel function of IRF6 activity, but instead reflects an ancient interaction that evolved as one feature of the innate immune response.

Methods {#S12}
=======

Dissociation of zebrafish embryos, FACS and RNA preparation {#S13}
-----------------------------------------------------------

For production of the periderm-enriched profile, about 200 heterozygous transgenic *tg(krt4:gfp)*([@R13]) embryos were reared to 11 hpf, pestle homogenized, and dissociated with phosphate buffered saline (PBS) containing 0.25% trypsin and 1 mM EDTA (Gibco \# 25200, Invitrogen, Carlsbad, CA) for 30 minutes at 33°C. Cells were resuspended in PBS plus 3% fetal bovine serum (FBS) and sorted on a FACS DiVa (Becton Dickinson, Franklin Lakes, NJ), directly into a buffer containing guanidinium thiocyanate for subsequent RNA isolation using the RNEasy Plus Mini Kit (i.e., Buffer RLT, QIAGEN, Valencia, CA). RNA was subjected to two rounds of amplification using the Message Amp II aRNA Amplification Kit (Invitrogen). For production of the dnIrf6-inhibited profile, embryos were injected with *dnIrf6* or the *lacZ* mRNA, raised to 6 hpf and homogenized. RNA was extracted from the *dnIrf6*- or control-RNA injected embryos as described above, without an amplification step. RNA was pooled from a total of approximately 100 embryos of each type; both types were generated on two separate injection days.

cDNA preparation and probe hybridization {#S14}
----------------------------------------

For production of the periderm-enriched profile, we synthesized and labeled cDNA a single time, and hybridized 6 arrays each with the two classes of probes, using cDNA microarrays in the 12-plex format (Design number 090505_Zv7_EXPR_HX12, Roche NimbleGen, Madison, WI). The periderm-enriched profile was thus generated from a single biological replicate (of about 200 animals) and 6 technical replicates. Based on technical replicates, the FDR-adjusted p values for all genes in the periderm profile were lower than 10^−8^. For the dnIrf6-inhibited profile, three cDNA synthesis reactions were performed on the pooled RNA, probes were generated from each cDNA preparation, and three arrays (technical replicates) were hybridized with each probe reaction. Differentially expressed genes were selected based on an FDR-adjusted p-value cutoff of 0.05, and a fold-change cutoff of 1.7. Because the periderm-enriched and dnIrf6-inhibited profiles were created from embryos at different ages, the periderm-enriched profile was filtered of all genes whose expression at 6 hpf in lacz-injected embryos was not above threshold (defined in [Supplememental Methods](#SD1){ref-type="supplementary-material"}) before overlap between the two profiles was evaluated.

Reporter experiments {#S15}
--------------------

Construction of reporters to test enhancer function of the human and mouse genomic elements is described in [Supplemental Methods](#SD1){ref-type="supplementary-material"}. At 24 hpf, 20% (20 of 97 injected embryos) of zebrafish embryos injected with *hGRHL3_peak2:gfp* exhibited patches of 10 or more GFP-positive periderm cells, whereas none of those injected with *hGRHL3_peak1:gfp* (30 injected embryos), or with the pGW_cfosEGFP vector lacking an insert (28 injected embryos), did so.

For both the wild-type Irf6RE and the Irf6RE variant, embryos were injected with 5 nl of plasmid (0.05 ng/μl) plus *tol2* mRNA (25ng/μl) at the single-cell stage. Embryos at shield stage (6 hpf) were scored, using a Leica epifluorescence compound microscope, for GFP expression in greater than 10 contiguous periderm cells (*mGrhl3intron15:gfp*, 40%, n=79 embryos; 0%, *intron15 ΔIrf6RE*, n=91 embryos). A 5 μm step z-stack was taken and the "auto-blend" feature of Photoshop CS3 was used to merge it into a single image ([Fig. 2F](#F2){ref-type="fig"}). We raised injected founders and identified two that transmitted GFP in the F1 generation. One exhibited high-level GFP expression throughout the periderm, like the transient transgenic embryos (shown in [Fig 2H](#F2){ref-type="fig"}); the other exhibited GFP expression in facial periderm, in hatching gland cells, and in unidentified oral structures.

Supplementary Material {#S16}
======================

###### 

**Figure S1 Western blot analysis of lysates of zebrafish eggs and embryos.** Western blot analysis of zebrafish embryo lysates, gel loaded with lysates of embryos at the indicated stage, from uninjected or *irf6* 5′UTR MO-injected embryos as indicated. Anti-Irf6 immunoreactivity detected in lysates of unfertilized eggs and 2hpf (128-cell stage) embryos supports the presence of maternally-encoded Irf6 at these stages. Irf6 immunoreactivity in lysates of *irf6* 5′UTR MO-injected embryos is slightly reduced, supporting the specificity of the antisera. Blot was reprobed with anti-alpha-Tubulin to confirm similar levels of protein were loaded in each lane.

**Figure S2 A morpholino targeting E4I4of *grhl3* prevents proper splicing** A. An antisense morpholino targeting E4I4of grhl3 (red) prevents proper splicing. Primers (green) were designed to lie in exon 4 and exon 6 of *grhl3 (*black). The larger splicing product (arrow) was cloned and sequenced to reveal that intron 4 (lower case) was not spliced from the transcript and contained a premature stop codon. cDNA synthesis was also performed with nuclease free water as a negative control (-RT). This cDNA template yielded no PCR products (not shown).

###### 

**Supplemental Table S1 Periderm-enriched profile.** These are all genes whose average expression (across technical replicates) in GFP-expressing cells was greater than 300 units (average expression among all probes was about 1500 units) and whose expression in GFP-expressing cells was at least 3 fold greater than in GFP-non-expressing cells. Genes that match the gene ontology (GO) term, "regulation of transcription, DNA dependent" ([www.http://david.abcc.ncifcrf.gov/](www.http://david.abcc.ncifcrf.gov/)) are in bold. Note this GO term may not capture all transcription-factor-encoding genes.

**Supplemental Table S2 dnIrf6-inhibited profile.** These are genes whose average expression (across biological replicates) in control (*lacZ*-injected) embryos was significantly higher (FDR adj. p value \< 0.05) than in *dnIrf6*-injected embryos.

**Supplemental Table S3** The intersection of periderm-enriched and dnIrf6-inhibited profiles.
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![Microarray analysis of zebrafish periderm\
**a,c** Schematic representation of methods used to create the periderm-enriched (**a**) and the dnIrf6-inhibited (**c**) profile. **b,d,** Pie charts showing genes whose expression is **b** 3× higher in FACS-sorted GFP-positive versus GFP-negative cells (**c**) or significantly reduced (\>1.7 fold) in *dnIrf6-*injected compared to *lacZ-*injected embryos (**d**). **e** Venn diagram portraying the overlap of sets in **b** and **d. f--y** Animal-pole view of mid-gastrula stage embryos, uninjected or injected with *dnIrf6*, and processed to reveal expression of the indicated gene. All are expressed in periderm and all except **y** (*epcam)* are strongly reduced in dnIrf6-injected embryos. Scale bar: **f**, 100 μM. **z** qRT-PCR for genes whose expression is reduced by *dnIrf6* and significantly elevated (with respect to dnIrf6 alone) by co-injection with *Irf6* (p \<0.05).](nihms393605f1){#F1}

![Enhancer activity of DNA elements near *GRHL3*\
**a** Positions of Irf6 binding peaks in human keratinocytes from a ChIP-SEQ experiment ([@R6]), and construction of luciferase and GFP reporter vectors with these peaks. **b** Results of luciferase reporter assay. **c,f,g,h** Transient (**c,f,g**) and stable (**h**) transgenic zebrafish embryos of the indicated constructs with GFP expression in the periderm. **d** Schematic representation of a conserved element within *GRHL3* intron 15 (gray box), which contains a conserved Irf6 response element (IRF6-RE). Position-weighted matrix for IRF6-RE defined *in vitro* ([@R22]) and *in vivo* ([@R6]). **e** Electromobility shift assay with human IRF6DBD and a labeled probe that matches 25 base pairs of the *hGrhl3 intron 15* that encompass the putative Irf6RE. Scale bars: **c**, 100 μm; **f**, 200 μm.](nihms393605f2){#F2}

![Knockdown of *grhl* family members results in loss of periderm markers\
**a,b** Animal-pole view of 8hpf embryos injected mosaically with **a**, biotinylated dextran mixed with *lacZ* or **b**, *dnXgrhl1* mRNA. Embryos were fixed at shield stage and processed to reveal *krt4* expression (purple) and biotin (brown). Periderm cells inheriting *lacZ* (brown nuclei) express *krt4* variably, like periderm cells in uninjected embryos, while those inheriting *dnXGrhl1* (brown nuclei) lack *krt4*. **c--j** Embryos injected with control MO (**c,e,g,i**), or *grhl1* and *grhl3* MOs (**d,f,h,j**), fixed at 8 hpf, and processed to reveal expression of the indicated gene, or allowed to develop until 10 hpf (**i--j**), at which time control MO-injected embryo have normal morphology (**i**), and *grhl1/grhl3* MO-injected embryos have ruptured (**j**). Scale bars: **a**, 50 μm; **a inset** 10 μm; **c**, 100 μm; **i**, 100 μm.](nihms393605f3){#F3}

![Injection of *grhl3* restores periderm markers in *dnIrf6*-injected embryos\
**A--I** Images of live (**a--f**) and DAPI-stained sections of (**g--i**) embryos injected with the indicated RNA. Insets, magnified images of the boxed area. **g--i** The doming of the yolk apparent in lacz-injected embyros (**g**), is lost in *dnIrf6*-injected embryos (**h**), and partially restored in *dnIrf6*-and-*grhl3* -injected embryos (**i**). **j** qRT-PCR analysis of mRNA levels. *capn9,* p=0.03, *cldnE,* p=0.003, *ovol1,* p=0.048.**k--m** 5-hpf embryos processed for *capn9* expression. **n** qRT-PCR analysis of levels of the periderm marker *xk81a1*, and the deep blastomere marker *sox11*, in *Xenopus* embryos derived from oocytes injected with control MO or *irf6* MO and injected as zygotes with the *XGrhl3* mRNA, as indicated. By ANOVA analysis, *xk81a1,* p\< 0.0002, *sox11*, p\< 0.03. Error bars, standard deviation. Scale bars: **a**, 200 μm; **g**, 100 μm.](nihms393605f4){#F4}

![Expression of Grhl3 in *Irf6*-deficient mice\
**a** qRT-PCR analysis of *Grhl3* levels in epidermis harvested at the indicated stage: e14.5, 2 replicates; e17.5, 3 replicates; p\<0.03. **b--e** Anti-Grhl3 immunofluorescence on the indicated tissue at the indcates stages. In the epidermis of sibling control embryos (**b**), Grhl3 immunoreactivity (IR) is prominent in all epidermal and peridermal nucleii. In mutant embyros (**c**), Grhl3 IR is diffuse, non-nuclear, and weak to undetectable in the periderm. In the oral epithelium of control siblings (**d**), Grhl3 IR is strong in in all nuclei, and strongest in the oral periderm. In mutant embryos (**e**), Grhl3 IR is highly reduced. Scale bar: **b**, 50 μm.](nihms393605f5){#F5}

###### 

Genes encoding transcription factors in both the periderm-enriched and dnIrf6-inhbited profiles

  Gene ID              Gene name
  -------------------- ---------------------------------------------------------------------------
  ENSDART00000082425   GATA-binding protein 2a
  ENSDART00000021159   LIM homeobox 1b
  ENSDART00000080693   LIM homeobox 5
  ENSDART00000060861   forkhead box P2
  ENSDART00000025153   GATA-binding protein 3
  ENSDART00000052521   nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1
  ENSDART00000052570   paired-like homeodomain transcription factor 2
  ENSDART00000017456   ventral expressed homeobox
  ENSDART00000087454   Grainyhead-like 1
  ENSDART00000059188   klf2b, Kruppel-like factor 2b
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